Cancer risk in patients aged 30 years and above with type 2 diabetes receiving antidiabetic monotherapy: a cohort study using metformin as the comparator

Overview of attention for article published in Therapeutics and Clinical Risk Management, August 2015

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 3,717 followers.

Cancer risk in patients aged 30 years and above T2D receiving antidiabetic monotherapy using metformin http://t.co/1TsdfdkzrB

Cancer risk in patients aged 30 years and above T2D receiving antidiabetic monotherapy using metformin http://t.co/NlwKkSNoTP

Cancer risk in patients aged 30 years and above T2D receiving antidiabetic monotherapy using metformin http://t.co/EekATeBAzy

Antidiabetic monotherapy and cancer risk http://t.co/r1FexDJPB4

Antidiabetic monotherapy and cancer risk http://t.co/6Td9enFNBh

Antidiabetic monotherapy and cancer risk http://t.co/pi4kxCaQDo